Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Puretech Health Plc ADR
(NQ:
PRTC
)
28.68
UNCHANGED
Streaming Delayed Price
Updated: 12:04 PM EDT, May 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Puretech Health Plc ADR
< Previous
1
2
3
4
5
Next >
PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp.
July 19, 2021
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)
July 09, 2021
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Sonde Health Announces Collaboration with Qualcomm Technologies for Use of Vocal Biomarker Technology on Qualcomm Snapdragon Mobile Platforms
July 08, 2021
From
PureTech Health plc
Via
Business Wire
PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors
July 07, 2021
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Vedanta Biosciences Announces New Data from Phase 1 Study of VE202 for the Treatment of Inflammatory Bowel Disease
June 30, 2021
From
PureTech Health plc
Via
Business Wire
Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)
June 29, 2021
From
Vedanta Biosciences
Via
Business Wire
PureTech Founded Entity Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers
June 23, 2021
From
PureTech Health plc
Via
Business Wire
PureTech Acquires Remaining Interest in Founded Entity Alivio Therapeutics
June 16, 2021
From
PureTech Health plc
Via
Business Wire
Results of Annual General Meeting
May 27, 2021
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Gelesis Presents Findings on Plenity®-Induced Weight Loss at the American Association of Clinical Endocrinology (AACE) 2021 Annual Virtual Meeting
May 27, 2021
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Akili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital Therapeutics
May 26, 2021
From
PureTech Health plc
Via
Business Wire
PureTech to Present at the Jefferies Virtual Healthcare Conference
May 25, 2021
From
PureTech Health plc
Via
Business Wire
PureTech Forms Clinical Advisory Board for Idiopathic Pulmonary Fibrosis and Related Lung Disorders
May 12, 2021
From
PureTech Health plc
Via
Business Wire
PureTech Announces Nature Publication Supporting Modulation of Meningeal Lymphatics to Target Alzheimer’s Disease Pathologies
April 28, 2021
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Gelesis Appoints Procter & Gamble Veteran Jane Wildman to Board of Directors
April 26, 2021
From
PureTech Health plc
Via
Business Wire
Vedanta Biosciences to Present at the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit
April 15, 2021
From
Vedanta Biosciences
Via
Business Wire
PureTech Announces Annual Results for Year Ended December 31, 2020
April 15, 2021
From
PureTech Health plc
Via
Business Wire
PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research (AACR) Annual Meeting
April 12, 2021
From
PureTech Health plc
Via
Business Wire
PureTech to Present at Two Upcoming Investor Conferences
April 07, 2021
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Akili Collaborates with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to Study Digital Therapeutic AKL-T01 as Potential Treatment for Patients with COVID Brain Fog
April 07, 2021
From
PureTech Health plc
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.